|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tempero MA, Malafa MP, Al-Hawary M, Asbun
H, Bain A, Behrman SW, Benson AB III, Binder E, Cardin DB, Cha C,
et al National Comprehensive Cancer Network Clinical Practice
Guidelines in Oncology, : Pancreatic Adenocarcinoma, Version
2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr
Canc Netw. 15:1028–1061. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Satoi S, Yamaue H, Kato K, Takahashi S,
Hirono S, Takeda S, Eguchi H, Sho M, Wada K, Shinchi H, et al: Role
of adjuvant surgery for patients with initially unresectable
pancreatic cancer with a long-term favorable response to
non-surgical anti-cancer treatments: Results of a project study for
pancreatic surgery by the Japanese Society of
Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci.
20:590–600. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Asano T, Hirano S, Nakamura T, Okamura K,
Tsuchikawa T, Noji T, Nakanishi Y, Tanaka K and Shichinohe T:
Survival benefit of conversion surgery for patients with initially
unresectable pancreatic cancer who responded favorably to
nonsurgical treatment. J Hepatobiliary Pancreat Sci. 25:342–350.
2018. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Okura R, Takano S, Yokota T, Yoshitomi H,
Kagawa S, Furukawa K, Takayashiki T, Kuboki S, Suzuki D, Sakai N,
et al: Conversion surgery with gemcitabine plus nab-paclitaxel for
locally advanced unresectable pancreatic cancer: A case report. Mol
Clin Oncol. 9:389–393. 2018.PubMed/NCBI
|
|
6
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Saito T, Ishido K, Kudo D, Kimura N,
Wakiya T, Nakayama Y and Hakamada K: Combination therapy with
gemcitabine and nab-paclitaxel for locally advanced unresectable
pancreatic cancer. Mol Clin Oncol. 6:963–967. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Blazer M, Wu C, Goldberg RM, Phillips G,
Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J,
Ellison EC, et al: Neoadjuvant modified (m) FOLFIRINOX for locally
advanced unresectable (LAPC) and borderline resectable (BRPC)
adenocarcinoma of the pancreas. Ann Surg Oncol. 22:1153–1159. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Marchegiani G, Todaro V, Boninsegna E,
Negrelli R, Sureka B, Bonamini D, Salvia R, Manfredi R, Pozzi
Mucelli R and Bassi C: Surgery after FOLFIRINOX treatment for
locally advanced and borderline resectable pancreatic cancer:
Increase in tumour attenuation on CT correlates with R0 resection.
Eur Radiol. 28:4265–4273. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Muranaka T, Kuwatani M, Komatsu Y, Sawada
K, Nakatsumi H, Kawamoto Y, Yuki S, Kubota Y, Kubo K, Kawahata S,
et al: Comparison of efficacy and toxicity of FOLFIRINOX and
gemcitabine with nab-paclitaxel in unresectable pancreatic cancer.
J Gastrointest Oncol. 8:566–571. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ueno H, Ioka T, Ikeda M, Ohkawa S,
Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, et
al: Randomized phase III study of gemcitabine plus S-1, S-1 alone,
or gemcitabine alone in patients with locally advanced and
metastatic pancreatic cancer in Japan and Taiwan: GEST study. J
Clin Oncol. 31:1640–1648. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van Veldhuisen E, Vogel JA, Klompmaker S,
Busch OR, van Laarhoven HWM, van Lienden KP, Wilmink JW, Marsman HA
and Besselink MG: Added value of CA19-9 response in predicting
resectability of locally advanced pancreatic cancer following
induction chemotherapy. HPB (Oxford). 20:605–611. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Boone BA, Steve J, Zenati MS, Hogg ME,
Singhi AD, Bartlett DL, Zureikat AH, Bahary N and Zeh HJ III: Serum
CA 19-9 response to neoadjuvant therapy is associated with outcome
in pancreatic adenocarcinoma. Ann Surg Oncol. 21:4351–4358. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Alvarez R, Musteanu M, Garcia-Garcia E,
Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A,
Rodriguez-Pascual J, et al: Stromal disrupting effects of
nab-paclitaxel in pancreatic cancer. Br J Cancer. 109:926–933.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hamada T, Yasunaga H, Nakai Y, Isayama H,
Matsui H, Fushimi K and Koike K: Interstitial lung disease
associated with gemcitabine: A Japanese retrospective cohort study.
Respirology. 21:338–343. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Umemura S, Yamane H, Suwaki T, Katoh T,
Yano T, Shiote Y, Takigawa N, Kiura K and Kamei H: Interstitial
lung disease associated with gemcitabine treatment in patients with
non-small-cell lung cancer and pancreatic cancer. J Cancer Res Clin
Oncol. 137:1469–1475. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nakaya A, Kurata T, Yokoi T, Takeyasu Y,
Niki M, Kibata K, Satsutani N, Torii Y, Katashiba Y, Ogata M, et
al: Retrospective analysis of single-agent nab-paclitaxel in
patients with platinum-resistant non-small cell lung cancer. Mol
Clin Oncol. 7:803–807. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Okusaka T, Ikeda M, Fukutomi A, Ioka T,
Furuse J, Ohkawa S, Isayama H and Boku N: Phase II study of
FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic
pancreatic cancer. Cancer Sci. 105:1321–1326. 2014. View Article : Google Scholar : PubMed/NCBI
|
